Latest Profit Guidance News

Judo Capital Holdings clarifies its recent Q3 financial disclosures, affirming compliance with ASX rules while highlighting FY26 profit guidance as material information.

AUB Group Limited has upgraded its FY25 underlying net profit guidance to the upper end of its previously announced range, buoyed by favourable trading conditions and strategic FX hedging.

Locality Planning Energy Holdings Ltd (ASX: LPE) reports a cashflow positive nine months to March 2025, confirms no material impact from Cyclone Alfred, and announces key board appointments to support growth.

Harmoney has raised its FY25 cash NPAT guidance to $5.5 million and announced an on-market share buy-back, setting the stage for accelerated loan book growth and improved returns in FY26.

Aroa Biosurgery reports a second consecutive quarter of positive operating cash flow and record sales for its Myriad product line, while maintaining full-year FY25 revenue and EBITDA guidance.

SEEK Limited reported robust half-year results for FY2025, with gains in placement share and yield offsetting volume declines, alongside a significant rise in free cash flow and an increased interim dividend.

SRG Global has reported a record first half for FY25, posting a 21% revenue increase and upgrading its full-year profit guidance, driven by strong cash flow and successful integration of the Diona acquisition.

Turners Automotive Group has raised its FY25 profit guidance to at least NZ$53 million, marking its fifth consecutive record profit despite challenging economic conditions.

Judo Bank has reported a robust half-year performance with a 70% jump in statutory net profit, driven by strong loan growth and improved margins, while reaffirming its FY25 profit guidance.

Kina Securities confirms its 2024 underlying profit guidance amid a non-cash statutory profit reduction driven by deferred tax asset adjustments and a customer fraud impact.

CSL Limited reported a solid 5% revenue increase and 6% rise in net profit after tax for the half year ended December 2024, underpinned by robust performance in its plasma therapies business despite headwinds in its influenza vaccine segment.

Nick Scali Limited reported a robust 1H FY25 with revenue growth and profits exceeding guidance, despite ongoing UK market disruptions and restructuring costs.